These 60-minute sessions are scheduled before and after 2016 AACC Clinical Lab Expo hours and located close to the Exhibit Hall at the Marriott Philadelphia Downtown. Additionally, these workshops may offer continuing education credits.
TUESDAY, AUGUST 2
A treatment for hypophosphatasia is now available; however, a conundrum exists. Data is sparse in healthy subjects to provide age-specific reference ranges and little attention is given to low ALP levels to recognize the broad ranging expressivity. Education is needed for medical professionals and in particular, laboratory directors, who could be instrumental in establishing and advising of appropriate reference ranges of ALP and subsequently, remarkable clinical findings.
Analytical differences between cardiac biomarkers are known based on performance evaluations, manufacturer product inserts, and regulatory claims that are well understood in the laboratory. However, the analytical characteristics and how they impact patient management, outcomes and healthcare institutions is not always expressed in such analysis.
The workshop will focus on research representing the value of implementing state of the art cardiac assays and the impact that may be expected to patient management and outcomes as well as the healthcare institution.
Statistical quality control (QC) is the primary tool used by clinical laboratories to identify changes in stable operation of a measurement procedure. Most labs are familiar with CLSI’s C24 – Statistical QC for Quantitative Measurement Procedures. In 2016, the 4th edition of C24 containing significant updates was released. This session will review the CLSI document and highlight key changes with a focus on practical examples.
Provide attendees with guidance to help them meet IQCP requirements and review materials available from Siemens Healthcare. They will also obtain advice specific to their lab in a Q&A session at the end of the event.
A new diagnostic platform will be presented that uses the measurement of heat from chemical or enzyme-catalyzed reactions as its foundation. The Thermal ELISA format will be explained in detail and data will be presented for the rapid detection of a virus and Herceptin (Trastuzumab) in nanoliter sample volumes. The simplicity of the system allows for an affordable diagnostic point-of-care or research laboratory system that delivers high sensitivity and specificity. Its simplicity would allow it to be used in a resource-limited, World Health Organization, or military setting, or a high-throughput drug discovery environment.
Cardiac marker, especially cardiac troponin (cTn), plays a significant role in the diagnosis of AMI patients. A high-sensitivity cTn (hs-cTn) test could enable earlier detection of troponin levels and thus, early rule out with superior NPV as compared to conventional cTn. This session will discuss how a new rapid, high-sensitivity point-of-care test (POCT) for cTn makes an impact on patient management and health economics. Future perspectives of new high-sensitive POCT will also be presented.
Join us to learn about the world’s smallest molecular diagnostics device that enables anyone to perform DNA testing from sample to result in a fraction of the time compared to traditional lab-based testing. The Spartan Cube is a PCR-based platform for a variety of molecular diagnostic applications, including infectious disease and pharmacogenetic testing. Attend this workshop to learn more about this exceptionally small system, its key features, and our assay menu. This workshop will also provide insights into how Spartan is reimagining patient-centered outcomes in light of this new and emerging diagnostic approach.
Historically, researchers have utilized technologies that allow them to look at single kinases in a relatively linear fashion. Learn how studying the kinome as a whole entity, using additional technologies like high resolution quantitative mass spectrometry, can aid in understanding how tumors may evade current therapies by altering their kinome state. Using this information, attendees will also learn how clinical translation researchers are investigating new and potentially more effective kinase inhibitor combination therapies for complex diseases like cancer.
Protein electrophoresis and IFE have been relied upon to aid in the detection and monitoring of plasma cell dyscrasia for many years. The technique of interpretation of protein and IFE patterns will be discussed. New approaches to myeloma treatment can sometimes alter the impression of patterns. Suggestions for more accurate reporting of bands will be offered. The importance of gauging the efficacy of treatment will be reviewed. New software allows for more accurate monitoring of progress in treatment of myeloma patients.
The laboratory is the heart of the hospital, circulating results and feeding clinicians the answers needed to make decisions. Quality control (QC) is the systemic heartbeat of the laboratory – thus the heartbeat of the hospital. This workshop highlights Dr. Westgard’s foundational principles which continue to enable innovations in QC strategies. The workshop uncovers the impact of high-quality performance through case studies and highlights how laboratories have reduced costs and maximized labor savings - all enabled by six sigma quality. In addition, Sigma-metrics can reveal the quality of methods, instruments, and manufacturers through global data mining of PT/EQA programs.
WEDNESDAY, AUGUST 3
Continuing consolidation of care delivery networks and broader adoption of the alternative reimbursement models present new challenges to the clinical laboratory. Conversely, the tighter integration of the laboratory into the clinical care continuum and adoption of new technologies will help the laboratory to elevate its profile and exert higher influence over the delivery of care. This workshop will present and debate a number of alternative strategies and tactical steps laboratories can pursue to build their clinical and economic contribution in different care settings.
The CMS Core Quality Measures for Sepsis are designed to aid in managing patients with severe sepsis and septic shock. This workshop examines the CMS measures from the perspective of laboratorians, physicians, and nurses, and how an on-site procalcitonin (PCT) assay plays a role in rapidly assessing the risk of progression to sepsis and the patient’s risk for mortality.
Laboratory test utilization is important because it directly impacts our ability to decrease diagnostic errors and minimize unnecessary expenses for the patient, laboratory, and hospital. This workshop describes the nature of misutilization, and describes interventions to overcome the most significant utilization problems. These interventions include both simple and complex improvements in information technology as well as a variety of best practice ideas for collaboration between laboratorians and ordering physicians. The overall goal of the workshop is to make laboratory professionals a more effective part of the diagnostic team that will help contribute to a healthier hospital.
Facing shrinking budgets, growing workloads, and an increasing number of tests per sample, labs are looking for ways to automate STAT and routine hemostasis testing while streamlining complex, multidisciplinary workflows.
Additionally, preanalytical errors in hemostasis testing have a major impact on TAT, workflow efficiency, and the accuracy and quality of results, thereby impacting patient care. Today’s healthcare providers need automated and standardized preanalytical sample integrity checks, automation connectivity and result comparability to simplify testing across multisite labs.
This workshop aims to address these issues and share approaches that hemostasis labs can use to overcome workflow challenges and achieve better patient outcomes.
The troponin assay has undergone tremendous changes in terms of sensitivity since its inception. A media storm surrounds the newest assays, but is higher sensitivity the key to making a sound clinical decision?
Lipoprotein electrophoresis has been a utilized technology in the clinical laboratory since the 1960s. Agarose electrophoresis, with cholesterol staining, has more recently been used as a means to quantitate lipoprotein (a) [Lp(a)] cholesterol. Lp(a) was discovered in the early 1960s and has been associated with cardiovascular disease in many studies. This educational session will describe why Lp(a) is atherogenic and the reason for the difficulty of measurement. Results from the JUPITER trial will be reviewed. In addition, staining of electrophoretic patterns for triglycerides can now be accomplished. The triglyceride content of lipoprotein particles may actually provide more relevant clinical information than lipoprotein cholesterol measures. The method for such analysis will be described and the clinical implications discussed in this symposium.